

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/661,948	10/661,948 09/12/2003		Eli D. Ehrenpreis	27373/38613A	8386
4743	7590	08/15/2006	EXAMINER		INER
	•	STEIN & BORUN	SPIVACK, PHYLLIS G		
233 S. WAC SEARS TO		IVE, SUITE 6300	ART UNIT	PAPER NUMBER	
CHICAGO, IL 60606			1614		
				DATE MAILED: 08/15/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Cummons	10/661,948	EHRENPREIS, ELI D.					
Office Action Summary	Examiner	Art Unit					
	Phyllis G. Spivack	1614					
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the o	correspondence address					
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailir earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from the, cause the application to become ABANDONE	the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on							
,	s action is non-final.						
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) Claim(s) 1-40 is/are pending in the application							
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
8) Claim(s) 1-40 are subject to restriction and/or	election requirement.						
Application Papers							
9) The specification is objected to by the Examine	er.						
10)☐ The drawing(s) filed on is/are: a)☐ acc		Examiner.					
Applicant may not request that any objection to the							
Replacement drawing sheet(s) including the correct	ction is required if the drawing(s) is ob	jected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the E	xaminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document	ts have been received.						
2. Certified copies of the priority documents have been received in Application No3. Copies of the certified copies of the priority documents have been received in this National Stage							
3. ☐ Copies of the certified copies of the price application from the International Burea		ed in this National Stage					
* See the attached detailed Office action for a list	` ''	od.					
	tor and doramed dopred met receive						
Attachment(s)							
1) Notice of References Cited (PTO-892)	4) Interview Summary						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08	Paper No(s)/Mail Da	ate atent Application (PTO-152)					
Paper No(s)/Mail Date	6) Other:						

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-12, drawn to methods of monitoring gastric emptying, diagnosing a gastric emptying disorder and diagnosing gastroparesis in a mammal, classified in class 436, subclasses 50, 811.

- II. Claims 13-17, drawn to a method of screening for a compound that modulates gastrointestinal motility in a mammal, classified in class 436, subclass 815.
- III. Claims 18-40, drawn to formulations comprising D-xylose and a kit comprising a marker agent, classified in various subclasses of class 514, depending on the marker contemplated and class 514, subclass 23.

The inventions are distinct, each from the other, for the following reasons:

Inventions I, II and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the inventions have different effects. The D-Xylose absorption test is a relatively specific measurement of proximal small-bowel absorption.

The Groups have acquired a separate status in the art as shown by their different classification and their recognized, divergent subject matter. The searches required for each Group are not co-extensive resulting in an undue burden to the Examiner. Each Group is capable of supporting a separate patent. Thus restriction for examination purposes as indicated is proper.

Further, claims 27-40 are generic to the following disclosed patentably distinct species: first and second marker agents. The species are independent or distinct

Art Unit: 1614

because a prior art reference anticipating claim 27 with respect to one species that is a first or second marker would not render the claim obvious under 35 U.S.C. 103 with respect to another species. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Applicant is advised that to be complete, the reply to this requirement must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Where the Examiner has required restriction between product and process claims and Applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after Final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to

Application/Control Number: 10/661,948

Art Unit: 1614

be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the Examiner before the patent issues withdraws the restriction requirement. See MPEP § 804.01.

A telephone call to the attorney is not required where: 1) the restriction requirement is complex; 2) the application is being prosecuted *pro se*; or, 3) the Examiner knows from past experience that a telephone election will not be made. See MPEP 812.01.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-0585. The Examiner can normally be reached on 10:30 AM-7 PM.

If attempts to reach the Examiner by telephone are unsuccessful after one business day, the Examiner's supervisor, Ardin Marschel, can be reached at 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

August 10, 2006

Phyllis G. Spivack

PHYLLIS SPIVACK PRIMARY EXAMINER